ABVC BioPharma Total Long Term Liabilities 2010-2024 | ABVC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ABVC BioPharma total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ABVC BioPharma total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.9B
Regeneron Pharmaceuticals (REGN)	$125.5B
Vertex Pharmaceuticals (VRTX)	$122.4B
Gilead Sciences (GILD)	$104.4B
Bristol Myers Squibb (BMY)	$100.8B
CSL (CSLLY)	$96.8B
GSK (GSK)	$87.9B
Alnylam Pharmaceuticals (ALNY)	$35.1B
Argenex SE (ARGX)	$31.6B
Biogen (BIIB)	$28.8B
BioNTech SE (BNTX)	$27.5B
Moderna (MRNA)	$26.9B
Illumina (ILMN)	$20.9B
BeiGene (BGNE)	$19.2B
Genmab (GMAB)	$17.3B
BioMarin Pharmaceutical (BMRN)	$13.5B
Vaxcyte (PCVX)	$13B
Exact Sciences (EXAS)	$12.8B
Incyte (INCY)	$12.6B
Insmed (INSM)	$12.5B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.4B
Bio-Rad Laboratories (BIO.B)	$9.1B
Legend Biotech (LEGN)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.7B
Repligen (RGEN)	$8B
Halozyme Therapeutics (HALO)	$7.9B
Intra-Cellular Therapies (ITCI)	$7.9B